Eris Lifesciences Employee Stock Options

Eris Lifesciences Investor Presentation: Key Takeaways

Q2 FY27 consolidated revenue ₹892 Cr (+12.6%), PAT ₹187 Cr (+39.2%), EBITDA margin 34.7%. H1 PAT ₹330 Cr (+27.3%). Zorvia out-licensing supports DBF gross margin.

Eris Lifesciences Q2 FY27 Results: Net Profit ₹187.1 Cr, Up 39.1% YoY

Eris Lifesciences Ltd reported revenue from operations of ₹892.4 Cr (+12.6% YoY) and net profit of ₹187.1 Cr (+39.1% YoY) for Q2 FY27.

Key figure

Net profit ₹187.1 Cr · +39.1% YoY

Eris Lifesciences Board Meeting Date

Eris Lifesciences has scheduled a board meeting for October 26, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter ending September.

Eris Lifesciences Other Announcement

Eris Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.

Eris Lifesciences Debt & Borrowing: ₹1,250 Cr

Eris Lifesciences Limited submitted its half-yearly reporting of debt securities for the period ended September 30, 2026. Two tranches of NCDs totaling ₹1,250 Crore remain outstanding.

Value

₹1,250 Cr

Eris Lifesciences Management Change

Eris Lifesciences Limited announced the resignation of Mr. Krishnakumar Vaidyanathan from his roles as Executive Director and Chief Operating Officer. The resignation was effective September 30, 2026.

Aye Finance Employee Stock Options

Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.

Aarti Pharmalabs Employee Stock Options

Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.

OnEMI Technology Solutions Employee Stock Options

OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.

Bliss GVS Pharma Employee Stock Options

Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.

Bandhan Bank Employee Stock Options

Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.

Maxvolt Energy Industries Employee Stock Options

Maxvolt Energy granted 5,01,726 ESOPs to six employees under its MEIL ESOP 2025 scheme at exercise prices of ₹30 and ₹45. Options vest over four years, with exercise windows following vesting.

Execution

Vesting over 4 years from grant (25% at 2nd, 25% at 3rd, 50% at 4th anniversary); exercise over 3 years from each vesting date